Arcus Biosciences RCUS Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -168.6%+141pp | -156.3%-28.4pp | -156.3%-35.3pp | -129%-10.4pp | -309.2%-195pp | |
| Net margin | -156.4%+121pp | -142.9%-33.2pp | -142.1%-39.4pp | -113.7%-12.9pp | -277.3%-180pp | |
| EBITDA margin | -164.8%+137pp | -152.2%-28.2pp | -152.1%-35.0pp | -125.2%-10.2pp | -302.1%-192pp | |
| Free cash flow margin | -207.2%— | -196%— | -193.3%— | —— | —— | |
| Returns | ||||||
| Return on equity | -70%-6.8pp | -63.3%-3.5pp | -68.1%-18.4pp | -50.3%-8.9pp | -63.2%-27.8pp | |
| Return on assets | -34.3%-2.3pp | -30.8%-5.6pp | -30.6%-8.5pp | -26.4%-5.7pp | -31.9%-13.8pp | |
| Return on invested capital | -95.3%-1.8pp | -70.1%-0.6pp | -102.6%-19.7pp | -75.1%— | -93.6%— | |
| Efficiency | ||||||
| Asset turnover | 0.2×+0.1× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.1×-0.1× | |
| Liquidity | ||||||
| Current ratio | 4×-1.3× | 4.4×-0.1× | 3.6×-1.6× | 4.5×-0.6× | 5.4×+0.2× | |
| Quick ratio | 4×-1.3× | 4.4×-0.1× | 3.6×-1.6× | 4.5×-0.6× | 5.4×+0.2× | |
| Cash ratio | 1×0.0× | 1×+0.3× | 1×+0.1× | 1.2×+0.4× | 1×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×+0.1× | 0.3×0.0× | 0.3×+0.2× | 0.2×+0.2× | 0.1×+0.1× | |
| Debt-to-assets | 0.1×+0.1× | 0.2×0.0× | 0.1×+0.1× | 0.1×+0.1× | 0.1×0.0× | |
| Interest coverage | -39.8×+69.2× | -48.3×+34.3× | -46.9×— | -56.3×— | -109×— | |
| Per Share | ||||||
| Book value per share | $4.18-22.6% | $5.88+9.1% | $4.09-33.8% | $5.15-26.0% | $5.40-34.2% | |
| Valuation | ||||||
| Market capitalization | $2.71B+226% | $2.95B+116% | $1.45B+3.9% | $926.49M-29.4% | $830.86M-48.9% | |
| Enterprise value | $2.62B+275% | $2.92B+113% | $1.32B+5.6% | $787.49M-32.6% | $698.86M-51.9% | |
| Price / sales | 11.5×+5.6× | 11.9×+6.7× | 6×+0.7× | 3.5×-1.8× | 5.9×-1.0× | |
| Price / book | 5.2×+3.6× | 4.7×+1.9× | 3.3×+0.9× | 1.7×-0.4× | 1.6×-0.7× | |
| EV / sales | 11.1×+6.1× | 11.8×+6.5× | 5.5×+0.7× | 3×-1.7× | 5×-1.2× | |
| Free cash flow yield | -18.1%— | -16.4%— | -32.1%— | —— | —— | |
| Earnings yield | -13.6%+33.4pp | -12%+8.8pp | -23.6%-4.2pp | -32.2%-13.2pp | -47.1%-32.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Arcus Biosciences's ratios come from?
- Every ratio is computed from Arcus Biosciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.